Peripheral Blood CD38 Bright CD8+ Effector Memory T Cells Predict Acute Graft-versus-Host Disease

Biology of Blood and Marrow Transplantation

Volumn 21, Issue 7, 2015, Pages 1215-1222

  Khandelwal, Pooja ^a   Lane, Adam ^a   Chaturvedi, Vijaya ^a   Owsley, Erika ^a   Davies, Stella M ^a   Marmer, Daniel ^a   Filipovich, Alexandra H ^a   Jordan, Michael B ^a   Marsh, Rebecca A ^a  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

Author keywords

CD38 bright CD8+ effector memory T cells (TEMs); Effector memory T cells; Graft versus host disease (GVHD) predictive biomarker

Indexed keywords

CD3 ANTIGEN; CD38 ANTIGEN; CD45 ANTIGEN; CD45RA ANTIGEN; CD8 ANTIGEN; CHEMOKINE RECEPTOR CCR7; FLUOROCHROME; BIOLOGICAL MARKER; CD38 PROTEIN, HUMAN; IMMUNOSUPPRESSIVE AGENT; MEMBRANE PROTEIN; MYELOABLATIVE AGENT;

ACUTE GRAFT VERSUS HOST DISEASE; ADOLESCENT; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANTIGEN EXPRESSION; ARTICLE; BLOOD SAMPLING; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; EFFECTOR MEMORY T CELL; FLOW CYTOMETRY; FOLLOW UP; GRAFT RECIPIENT; HUMAN; INCIDENCE; INCUBATION TIME; MEMORY T LYMPHOCYTE; SENSITIVITY AND SPECIFICITY; T LYMPHOCYTE ACTIVATION; TREATMENT DURATION; ACUTE DISEASE; ADVERSE EFFECTS; ALLOTRANSPLANTATION; CD8+ T LYMPHOCYTE; COMMON VARIABLE IMMUNODEFICIENCY; FEMALE; GENE EXPRESSION; GENETICS; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY TEST; IMMUNOLOGICAL MEMORY; IMMUNOLOGY; IMMUNOPHENOTYPING; INFANT; LYMPHOCYTE ACTIVATION; MALE; PATHOLOGY; PRESCHOOL CHILD; TRANSPLANTATION CONDITIONING;

ACUTE DISEASE; ADOLESCENT; ADULT; ANTIGENS, CD38; BIOMARKERS; CD8-POSITIVE T-LYMPHOCYTES; CHILD; CHILD, PRESCHOOL; COMMON VARIABLE IMMUNODEFICIENCY; FEMALE; GENE EXPRESSION; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY TESTING; HUMANS; IMMUNOLOGIC MEMORY; IMMUNOPHENOTYPING; IMMUNOSUPPRESSIVE AGENTS; INFANT; LYMPHOCYTE ACTIVATION; MALE; MEMBRANE GLYCOPROTEINS; MYELOABLATIVE AGONISTS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS;

EID: 84930578289     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2015.04.010     Document Type: Article

References (43)

1. Ferrara J.L., Levine J.E., Reddy P., Holler E. Graft-versus-host disease. Lancet 2009, 373:1550-1561.
2. Chen Y.B., Cutler C.S. Biomarkers for acute GVHD: can we predict the unpredictable?. Bone Marrow Transplant 2013, 48:755-760.
3. Harris A.C., Ferrara J.L., Levine J.E. Advances in predicting acute GVHD. Br J Haematol 2013, 160:288-302.
4. Miyamoto T., Akashi K., Hayashi S., et al. Serum concentration of the soluble interleukin-2 receptor for monitoring acute graft-versus-host disease. Bone Marrow Transplant 1996, 17:185-190.
5. August K.J., Chiang K.Y., Bostick R.M., et al. Biomarkers of immune activation to screen for severe, acute GVHD. Bone Marrow Transplant 2011, 46:601-604.
6. Kitko C.L., Paczesny S., Yanik G., et al. Plasma elevations of tumor necrosis factor-receptor-1 at day 7 postallogeneic transplant correlate with graft-versus-host disease severity and overall survival in pediatric patients. Biol Blood Marrow Transplant 2008, 14:759-765.
7. Liu D., Yan C., Xu L., et al. Diarrhea during the conditioning regimen is correlated with the occurrence of severe acute graft-versus-host disease through systemic release of inflammatory cytokines. Biol Blood Marrow Transplant 2010, 16:1567-1575.
8. Xiao B., Wang Y., Li W., et al. Plasma microRNA signature as a noninvasive biomarker for acute graft-versus-host disease. Blood 2013, 122:3365-3375.
9. Kaiser T., Kamal H., Rank A., et al. Proteomics applied to the clinical follow-up of patients after allogeneic hematopoietic stem cell transplantation. Blood 2004, 104:340-349.
10. Thiant S., Labalette M., Trauet J., et al. Plasma levels of IL-7 and IL-15 after reduced intensity conditioned allo-SCT and relationship to acute GVHD. Bone Marrow Transplant 2011, 46:1374-1381.
11. Thiant S., Yakoub-Agha I., Magro L., et al. Plasma levels of IL-7 and IL-15 in the first month after myeloablative BMT are predictive biomarkers of both acute GVHD and relapse. Bone Marrow Transplant 2010, 45:1546-1552.
12. Choi S.W., Kitko C.L., Braun T., et al. Change in plasma tumor necrosis factor receptor 1 levels in the first week after myeloablative allogeneic transplantation correlates with severity and incidence of GVHD and survival. Blood 2008, 112:1539-1542.
13. Willems E., Humblet-Baron S., Dengis O., et al. Elevations of tumor necrosis factor receptor 1 at day 7 and acute graft-versus-host disease after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning. Bone Marrow Transplant 2010, 45:1442-1448.
14. Paczesny S., Braun T., Lugt M.V., et al. Three biomarker panel at day 7 and 14 can predict development of grade II-IV acute graft-versus-host disease. [ASH Annual Meeting Abstracts] Blood 2010, 116:675.
15. Vander Lugt M.T., Braun T.M., Hanash S., et al. ST2 as a marker for risk of therapy-resistant graft-versus-host disease and death. NEngl J Med 2013, 369:529-539.
16. Zheng H., Matte-Martone C., Jain D., et al. Central memory CD8+ T cells induce graft-versus-host disease and mediate graft-versus-leukemia. JImmunol 2009, 182:5938-5948.
17. Grogan B.M., Tabellini L., Storer B., et al. Activation and expansion of CD8(+) T effector cells in patients with chronic graft-versus-host disease. Biol Blood Marrow Transplant 2011, 17:1121-1132.
18. Bolanos-Meade J., Wu J., Logan B.R., et al. Lymphocyte phenotype during therapy for acute graft-versus-host disease: a brief report from BMT CTN 0302. Biol Blood Marrow Transplant 2013, 19:481-485.
19. Sun Y., Tawara I., Toubai T., Reddy P. Pathophysiology of acute graft-versus-host disease: recent advances. Transl Res 2007, 150:197-214.
20. Sallusto F., Geginat J., Lanzavecchia A. Central memory and effector memory T cell subsets: function, generation, and maintenance. Ann Rev Immunol 2004, 22:745-763.
21. Sallusto F., Lenig D., Forster R., et al. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 1999, 401:708-712.
22. Zheng H., Matte-Martone C., Li H., et al. Effector memory CD4+ T cells mediate graft-versus-leukemia without inducing graft-versus-host disease. Blood 2008, 111:2476-2484.
23. Dutt S., Tseng D., Ermann J., et al. Naive and memory T cells induce different types of graft-versus-host disease. JImmunol 2007, 179:6547-6554.
24. Dutt S., Baker J., Kohrt H.E., et al. CD8+CD44(hi) but not CD4+CD44(hi) memory T cells mediate potent graft antilymphoma activity without GVHD. Blood 2011, 117:3230-3239.
25. Chen B.J., Deoliveira D., Cui X., et al. Inability of memory T cells to induce graft-versus-host disease is a result of an abortive alloresponse. Blood 2007, 109:3115-3123.
26. Zhang Y., Joe G., Zhu J., et al. Dendritic cell-activated CD44hiCD8+ T cells are defective in mediating acute graft-versus-host disease but retain graft-versus-leukemia activity. Blood 2004, 103:3970-3978.
27. Podgorny P.J., Liu Y., Dharmani-Khan P., et al. Immune cell subset counts associated with graft-versus-host disease. Biol Blood Marrow Transplant 2014, 20:450-462.
28. Soiffer R.J., Gonin R., Murray C., et al. Prediction of graft-versus-host disease by phenotypic analysis of early immune reconstitution after CD6-depleted allogeneic bone marrow transplantation. Blood 1993, 82:2216-2223.
29. Gratama J.W., Naipal A., Oljans P., et al. Tlymphocyte repopulation and differentiation after bone marrow transplantation. Early shifts in the ratio between T4+ and T8+ T lymphocytes correlate with the occurrence of acute graft-versus-host disease. Blood 1984, 63:1416-1423.
30. Paz Morante M., Briones J., Canto E., et al. Activation-associated phenotype of CD3 T cells in acute graft-versus-host disease. Clin Exp Immunol 2006, 145:36-43.
31. Quarona V., Zaccarello G., Chillemi A., et al. CD38 and CD157: a long journey from activation markers to multifunctional molecules. Cytometry B Clin Cytom 2013, 84:207-217.
32. Bhan A.K., Reinherz E.L., Poppema S., et al. Location of T cell and major histocompatibility complex antigens in the human thymus. JExp Med 1980, 152:771-782.
33. Miller J.D., van der Most R.G., Akondy R.S., et al. Human effector and memory CD8+ T cell responses to smallpox and yellow fever vaccines. Immunity 2008, 28:710-722.
34. Malavasi F., Deaglio S., Damle R., et al. CD38 and chronic lymphocytic leukemia: a decade later. Blood 2011, 118:3470-3478.
35. Ortolan E., Arisio R., Morone S., et al. Functional role and prognostic significance of CD157 in ovarian carcinoma. JNatl Cancer Inst 2010, 102:1160-1177.
36. Rosso R., Fenoglio D., Terranova M.P., et al. Relevance of CD38 expression on CD8 T cells to evaluate antiretroviral therapy response in HIV-1-infected youths. Scand J Immunol 2010, 71:45-51.
37. Savarino A., Bottarel F., Malavasi F., Dianzani U. Role of CD38 in HIV-1 infection: an epiphenomenon of T cell activation or an active player in virus/host interactions?. AIDS 2000, 14:1079-1089.
38. Deaglio S., Mallone R., Baj G., et al. CD38/CD31, a receptor/ligand system ruling adhesion and signaling in human leukocytes. Chem Immunol 2000, 75:99-120.
39. Glucksberg H., Storb R., Fefer A., et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation 1974, 18:295-304.
40. Lugthart G., van Ostaijen-Ten Dam M.M., Jol-van der Zijde C.M., et al. Early cytomegalovirus reactivation leaves a specific and dynamic imprint on the reconstituting T cell compartment long-term after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2014, 20:655-661.
41. Baggiolini M. Chemokines and leukocyte traffic. Nature 1998, 392:565-568.
42. Butcher E.C., Picker L.J. Lymphocyte homing and homeostasis. Science 1996, 272:60-66.
43. Reshef R., Luger S.M., Hexner E.O., et al. Blockade of lymphocyte chemotaxis in visceral graft-versus-host disease. NEngl J Med 2012, 367:135-145.